Central African Republic vs Timor-Leste: Access to anti-retroviral drugs, male
Central African Republic
61.0%
in 2024
Timor-Leste
62.0%
in 2024
Central African Republic rank
97th
Timor-Leste rank
94th
Access to anti-retroviral drugs, male over time
- Central African Republic
- Timor-Leste
How they compare
Timor-Leste currently reports 62.0% against 61.0% in Central African Republic, a difference of 1.0%.
The two have swapped places 2 times across 22 shared years of data; in 2000 it was Timor-Leste ahead.
Central African Republic ranks 97th and Timor-Leste ranks 94th of 141 countries.
Across the 3 decades both report, Central African Republic averaged higher in 2 and Timor-Leste in 1.
Head to head by decade
| Decade | Central African Republic | Timor-Leste | Difference | Ahead |
|---|---|---|---|---|
| 2000s | 3.3% | 0.6% | 2.7% | Central African Republic |
| 2010s | 24.1% | 13.9% | 10.2% | Central African Republic |
| 2020s | 53.0% | 53.4% | 0.4% | Timor-Leste |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher access to anti-retroviral drugs, male, Central African Republic or Timor-Leste?
- Timor-Leste, at 62.0% against 61.0% in Central African Republic as of 2024.
- What is the difference in access to anti-retroviral drugs, male between Central African Republic and Timor-Leste?
- 1.0%, with Timor-Leste ahead.
- How many years of comparable data are there for Central African Republic and Timor-Leste?
- 22 years are reported by both, from 2000 to 2024.
- How do Central African Republic and Timor-Leste rank globally for access to anti-retroviral drugs, male?
- Central African Republic ranks 97th and Timor-Leste ranks 94th of 141 countries.
- Where does this data come from?
- UNAIDS estimates, published as Access to anti-retroviral drugs, male (%). Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
The percentage of adult males living with HIV who are receiving antiretroviral therapy.